Encyclopedia

Bone Marrow

Also found in: Dictionary, Medical, Acronyms, Wikipedia.
(redirected from Hematopoietic stem cell transplantation)

bone marrow

[′bōn ‚mar·ō]
(histology)
A vascular modified connective tissue occurring in the long bones and certain flat bones of vertebrates.
McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, Copyright © 2003 by The McGraw-Hill Companies, Inc.
The following article is from The Great Soviet Encyclopedia (1979). It might be outdated or ideologically biased.

Bone Marrow

 

the tissue that fills the cavities of the bones in vertebrate animals and man. A distinction is made between red marrow, with a predominance of hematopoietic myeloid tissue, and yellow marrow, with a predominance of fatty tissue. Red marrow remains throughout life in the flat bones (ribs, sternum, and cranial and pelvic bones) and in the vertebrae and epiphyses of the long bones. In man, bone marrow constitutes approximately 1.5 percent of the body mass. The hematopoietic tissue in the cavities of the long bones is eventually replaced by fatty tissue and the marrow becomes yellow.

Red bone marrow is the main hematopoietic organ in man and other adult mammals. The red blood cells, granular leukocytes (neutrophils, eosinophils, basophils), blood platelets (thrombocytes), and marrow lymphocytes are produced by the red bone marrow. Bone marrow contains hematopoietic stem cells (approximately 0.1 percent of all its cells). Owing to their capacity for repeated division and development into all forms of hematopoietic and lymphoid cells, stem cells sustain hematopoiesis in the bone marrow and replace the white and red blood cells that are constantly being destroyed in the body. Bone marrow primarily consists of different series of maturing cells (erythroid, myeloid, lymphocytic megakaryocytic). All are produced and replenished by the stem cells, and some are capable of repeated division. The relative amount of maturing cells of the individual blood series and of more or less mature cellular forms of each series in bone marrow is an important characteristic of hematopoiesis. As the cells from the bone marrow mature, they enter the bloodstream. In addition to mature cells, some hematopoietic stem cells emerge from the bone marrow and migrate to other hematopoietic organs. The basis of bone marrow is reticular tissue, which forms the syncytium, in which the hematopoietic cells are distributed. The multiplication and maturation of these cells are largely dependent on their interaction with reticular tissue (which is also capable of forming bone, a phenomenon manifested during the healing of bone fractures). The rate of hematopoiesis in bone marrow can increase sharply. As a result, a substantial loss of blood cells (for example, in bleeding) or the destruction of many bone marrow cells is usually compensated for quickly. However, bone marrow (especially its stem cells) is highly sensitive to certain agents (for example, ionizing radiation). Therefore, the condition of bone marrow is one of the principal factors determining the body’s resistance to such agents.

REFERENCES

Zavarzin, A. A., and A. V. Rumiantsev. Kurs gistologii, 6th ed. Moscow, 1946.
Chertkov, I. L., and A. la. Fridenshtein. “Rodonachal’naia krovetvornaia kletka i ee differentsirovka.” Uspekhi sovremennoi biologii, 1966, vol. 62, no. 1.

A. IA. FRIDENSHTEIN

The Great Soviet Encyclopedia, 3rd Edition (1970-1979). © 2010 The Gale Group, Inc. All rights reserved.
Mentioned in
References in periodicals archive
Vucinic et al., "High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis," Blood, vol.
Bondanza, "Predicting the clinical outcome of allogeneic hematopoietic stem cell transplantation: the long and winding road toward validated immune biomarkers," Frontiers in Immunology, vol.
Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens.
This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin's disease, Non-Hodgkin lymphomas and multiple myeloma, revealed the company.
The eligible candidates must comply with the criteria as follows: (1) Age >15 years old; (2) patients underwent first auto-HSCT at Hematopoietic Stem Cell Transplantation Center of Blood Diseases Hospital, Chinese Academy of Medical Sciences between January 1, 1994 and February 28, 2014; (3) follow-up data were available.
TOKYO, Japan, February 6, 2014 -- REGiMMUNE Corporation has begun a Phase 2 study of its proprietary compound RGI-2001 for GvHD associated with hematopoietic stem cell transplantation.
Today, allogeneic hematopoietic stem cell transplantation (HSCT) is commonly used as treatment for hematological malignancies, immunodeficiencies, and inborn errors of metabolism [1].
Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood 2001;98:1687-94.
Alain Fischer, MD of the Hopital Necker in Paris, France and colleagues reported long-term results for 919 patients with primary immunodeficiencies treated with hematopoietic stem cell transplantation at 37 European Centers between 1968 and 1999.
The clinical trial HERACLES is a prospective multi-center study in four European countries to include patients that have received a first-line standard treatment of corticosteroids following allogeneic hematopoietic stem cell transplantation.
Omeros announced that the European Commission has adopted a decision designating OMS721 as an Orphan Medicinal Product in the European Union for treatment in hematopoietic stem cell transplantation, or HSCT.
Copyright © 2003-2025 Farlex, Inc Disclaimer
All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.